Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IBI362 in heart failure with preserved or mildly reduced ejection fraction and obesity
CTR20250152Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Apr 2025
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mazdutide in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and obesity (3 arms), sponsored by InnoCare Pharma. Primary endpoints: Change from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and Percent change from baseline in body weight. Started Apr 2025; status: active.
02
Drugs
mazdutide
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on CTR20250152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250152.